Cited by 229Cancer Immunotherapy and BiomarkersHepatocellular Carcinoma Treatment and PrognosisFerroptosis and cancer prognosis

The DOI matches its Crossref record; 205 of the 205 references it cites were found in a registry or an index.

Biomarkers for immunotherapy of hepatocellular carcinoma

Greten, Tim F., Villanueva, Augusto, Korangy, Firouzeh, Ruf, Benjamin, Yarchoan, Mark, Ma, Lichun, Ruppin, Eytan, Wang, Xin W.·2023·Nature Reviews Clinical Oncology

DOI 10.1038/s41571-023-00816-4

Open this paper in CoChat — free account

Abstract

Immune-checkpoint inhibitors (ICIs) are now widely used for the treatment of patients with advanced-stage hepatocellular carcinoma (HCC). Two different ICI-containing regimens, atezolizumab plus bevacizumab and tremelimumab plus durvalumab, are now approved standard-of-care first-line therapies in this setting. However, and despite substantial improvements in survival outcomes relative to sorafenib, most patients with advanced-stage HCC do not derive durable benefit from these regimens. Advances in genome sequencing including the use of single-cell RNA sequencing (both of tumour material and blood samples), as well as immune cell identification strategies and other techniques such as radiomics and analysis of the microbiota, have created considerable potential for the identification of novel predictive biomarkers enabling the accurate selection of patients who are most likely to derive benefit from ICIs. In this Review, we summarize data on the immunology of HCC and the outcomes in patients receiving ICIs for the treatment of this disease. We then provide an overview of current biomarker use and developments in the past 5 years, including gene signatures, circulating tumour cells, high-dimensional flow cytometry, single-cell RNA sequencing as well as approaches involving the microbiome, radiomics and clinical markers. Novel concepts for further biomarker development in HCC are then discussed including biomarker-driven trials, spatial transcriptomics and integrated 'big data' analysis approaches. These concepts all have the potential to better identify patients who are most likely to benefit from ICIs and to promote the development of new treatment approaches.

Integrity signals

Registry

Crossref · 10.1038/s41571-023-00816-4

Cites

205 of 205 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Cancer statistics, 2023
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citation
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
International Agency for Research on Cancer
National Cancer Institute (2020) · Definitions · doi:10.32388/pfg7jq · Cited by 9,394
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Hepatocellular carcinoma
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citation
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
Biomarkers Definitions Working Group (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,771
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974

Show all 205 references

Research works printed but not linked: 2

Hoang, D.-T. et al. Synthetic lethality-based prediction of cancer treatment response from histopathology images. Cell 3, 2487–2502.e13 (2023).
Cao, Y. et al. Predicting tumor immune microenvironment and checkpoint therapy response of head & neck cancer patients from blood immune single-cell transcriptomics. Preprint at bioRxiv https://www.biorxiv.org/content/10.1101/2023.01.17.524455v1 (2023). · DOI

Sorted by citations

Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
Kuo, H., Khan, K. A., & Kerbel, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00886-y · Cited by 140
Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy
Seyhan, D., Allaire, M., Fu, Y., Conti, F., Wang, X. W., Gao, B., & Lafdil, F. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01308-4 · Cited by 138
Self-citation
Extracellular Vesicles for Clinical Diagnostics: From Bulk Measurements to Single-Vesicle Analysis
Tran, H. L., Zheng, W., Issadore, D., Im, H., Cho, Y., Zhang, Y., Liu, D., Liu, Y., Li, B., Liu, F., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c00706 · Cited by 117
Cancer stem cells and niches: challenges in immunotherapy resistance
Pan, Y., Yuan, C., Zeng, C., Sun, C., Xia, L., Wang, G., Chen, X., Zhang, B., Liu, J., & Ding, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02265-2 · Cited by 117
Single-cell multi-omics in cancer immunotherapy: from tumor heterogeneity to personalized precision treatment
Le, J., Dian, Y., Zhao, D., Guo, Z., Luo, Z., Chen, X., Zeng, F., & Deng, G. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02426-3 · Cited by 118
Big data and artificial intelligence in cancer research
Wu, X., Li, W., & Tu, H. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.10.006 · Cited by 83
Spatial single-cell profiling and neighbourhood analysis reveal the determinants of immune architecture connected to checkpoint inhibitor therapy outcome in hepatocellular carcinoma
Salié, H., Wischer, L., D’Alessio, A., Godbole, I., Suo, Y., Otto-Mora, P., Beck, J., Neumann, O., Stenzinger, A., Schirmacher, P., et al. (2024) · Gut · doi:10.1136/gutjnl-2024-332837 · Cited by 78
Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma
Cappuyns, S., Piqué‐Gili, M., Esteban-Fabró, R., Philips, G., Balaseviciute, U., Pinyol, R., Gris‐Oliver, A., Vandecaveye, V., Abril‐Fornaguera, J., Montironi, C., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.12.016 · Cited by 81
Self-citation
Single-cell transcriptomic analysis reveals gut microbiota-immunotherapy synergy through modulating tumor microenvironment
Cao, M., Deng, Y., Hao, Q., Yan, H., Wang, Q., Dong, C., Wu, J., He, Y., Huang, L., Xia, X., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02226-7 · Cited by 76
Intelligent Modular DNA Lysosome-Targeting Chimera Nanodevice for Precision Tumor Therapy
Cui, M.-R., Zhang, D., Zheng, X. P., Zhai, H., Xie, M., Fan, Q., Wang, L., Fan, C., & Chao, J. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c10010 · Cited by 68
Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma
Zhu, C., Zhang, C., Wang, S., Xun, Z., Zhang, D., Lan, Z., Zhang, L., Chao, J., Liang, Y., Pu, Z., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008686 · Cited by 65
Immunotherapy for hepatocellular carcinoma
Childs, A., Aidoo-Micah, G., Maini, M. K., & Meyer, T. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101130 · Cited by 64
Crosstalk between gut microbiotas and fatty acid metabolism in colorectal cancer
Zhang, H., Tian, Y., Xu, C., Chen, M., Xiang, Z., Gu, L., Xue, H., & Xu, Q. R. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02364-5 · Cited by 53
Development of Polymethine Dyes for NIR‐II Fluorescence Imaging and Therapy
Chen, X., Li, J., Roy, S., Ullah, Z., Gu, J., Huang, H., Yu, C., Wang, X., Wang, H., Zhang, Y., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304506 · Cited by 48
Self-citation
Spatial patterns and MRI-based radiomic prediction of high peritumoral tertiary lymphoid structure density in hepatocellular carcinoma: a multicenter study
Long, S., Li, M., Chen, J., Zhong, L., Abudulimu, A., Zhou, L., Liu, W., Pan, D., Dai, G., Fu, K., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009879 · Cited by 45
Role of the gut microbiota in tumorigenesis and treatment
Liu, Q., Yang, Y., Pan, M., Yang, F., Yu, Y., & Qian, Z. (2024) · Theranostics · doi:10.7150/thno.91700 · Cited by 46
Integration of Clinical Trial Spatial Multiomics Analysis and Virtual Clinical Trials Enables Immunotherapy Response Prediction and Biomarker Discovery
Zhang, S., Deshpande, A. M., Verma, B. K., Wang, H., Mi, H., Yuan, L., Ho, W. J., Jaffee, E. M., Zhu, Q., Anders, R. A., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0943 · Cited by 47
Self-citation
Understanding gut dysbiosis for hepatocellular carcinoma diagnosis and treatment
Yu, J., Chen, X., Yang, X., & Zhang, B. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.06.003 · Cited by 40
Immunotherapy in liver cancer: overcoming the tolerogenic liver microenvironment
Liu, Y., Yang, H., Li, T. X., & Zhang, N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1460282 · Cited by 39
Hepatocellular Carcinoma Immunotherapy: Predictors of Response, Issues, and Challenges
Rizzo, A., Brunetti, O., & Brandi, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011091 · Cited by 41
Recent progress of microneedles in transdermal immunotherapy: A review
Ai, X., Yang, J., Liu, Z., Guo, T., & Feng, N. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124481 · Cited by 35
ACE2 Enhances Sensitivity to PD-L1 Blockade by Inhibiting Macrophage-Induced Immunosuppression and Angiogenesis
Xie, P., Guo, L., Yu, Q., Zhao, Y., Yu, M., Wang, H., Wu, M., Xu, W., Xu, M., Zhu, X., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0954 · Cited by 34
Efflux of N1-acetylspermidine from hepatoma fosters macrophage-mediated immune suppression to dampen immunotherapeutic efficacy
Liu, Z., Wu, C.-Y., Wu, R., Wang, J.-C., Huang, C.-X., Wang, X., Zhang, Y., Zheng, L., Chen, Y., Lao, X., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.05.006 · Cited by 39
Self-citation
Transfer learning radiomic model predicts intratumoral tertiary lymphoid structures in hepatocellular carcinoma: a multicenter study
Long, S., Li, M., Chen, J., Zhong, L., Dai, G., Pan, D., Liu, W., Yi, F., Ruan, Y., Zou, B., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011126 · Cited by 33
Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma
Qin, R., Jin, T., & Xu, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1326097 · Cited by 30
Galectin‐1‐Induced Tumor Associated Macrophages Repress Antitumor Immunity in Hepatocellular Carcinoma Through Recruitment of Tregs
Yu, X., Qian, J., Ding, L., Pan, C., Liu, X., Wu, Q., Wang, S., Liu, J., Shang, M., Su, R., et al. (2025) · Advanced Science · doi:10.1002/advs.202408788 · Cited by 29
Small-molecule-based targeted therapy in liver cancer
Ming, Y., Gong, Y., Fu, X., Ouyang, X., Peng, Y., & Pu, W. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.08.001 · Cited by 27
Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
Rana, P. S., Ignatz-Hoover, J. J., Guo, C., Mosley, A. L., Malek, E., Federov, Y., Adams, D., & Driscoll, J. J. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0931 · Cited by 28
Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: Long-term efficacy and biomarker exploration
Lin, Y., Ou, D., Su, Y., Hsu, C., Hsiao, C., Ko, B., Chen, S., Wang, J., Wang, J.-H., Wu, Y., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.08.035 · Cited by 32
Targeting GDF15 to enhance immunotherapy efficacy in glioblastoma through tumor microenvironment-responsive CRISPR-Cas9 nanoparticles
Zou, C., Liu, X., Wang, W., He, L., Yin, A., Cao, Z., Zhu, M., Wu, Y., Liu, X., Ma, J., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03182-8 · Cited by 26
Circulating Gut Microbe-Derived Metabolites Are Associated with Hepatocellular Carcinoma
Banerjee, R., Wehrle, C. J., Wang, Z., Wilcox, J. D., Uppin, V., Varadharajan, V., Mrdjen, M., Hershberger, C. E., Reizes, O., Yu, J. S., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12091946 · Cited by 25
Endosialin-positive CAFs promote hepatocellular carcinoma progression by suppressing CD8+ T cell infiltration
Gan, L., Lü, T., Lu, Y., Song, H., Zhang, J., Zhang, K., Lu, S., Wu, X., Nie, F., Di, S., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009111 · Cited by 29
Spatial single-cell omics: new insights into liver diseases
Suo, Y., Thimme, R., & Bengsch, B. (2025) · Gut · doi:10.1136/gutjnl-2024-332105 · Cited by 29
Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab
Myojin, Y., Babaei, S., Trehan, R., Hoffman, C., Kedei, N., Ruf, B., Benmebarek, M.-R., Bauer, K. C., Huang, P., Ma, C., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-334026 · Cited by 24
Self-citation
TREM2 promotes the formation of a tumor-supportive microenvironment in hepatocellular carcinoma
Guo, H., Wang, M., Ni, C., Yang, C., Fu, C., Zhang, X., Chen, X., Wu, X., Hou, J. W., & Wang, L. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03287-w · Cited by 30
PARK7-driven IGF2BP3–K76 lactylation mediates ferroptosis and HAIC resistance in hepatocellular carcinoma
Zhu, Z., Xia, X., Lu, Y., Li, D., He, X., Zhang, B., Xiong, G., Zhang, W., Liang, H., & Zhu, H. J. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103869 · Cited by 29
Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma
Bitar, R. D., Salem, R., Finn, R. S., Greten, T. F., Goldberg, S. N., & Chapiro, J. (2024) · Radiology · doi:10.1148/radiol.232875 · Cited by 25
Self-citation
A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Han, J. W., Lee, S. K., Kwon, J. H., Nam, S. W., Yang, H., Bae, S. H., Kim, J. H., Nam, H., Kim, C. W., Lee, H. L., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3978 · Cited by 22
RBM12 drives PD-L1-mediated immune evasion in hepatocellular carcinoma by increasing JAK1 mRNA translation
Han, H., Shi, Q., Zhang, Y., Ding, M., He, X.-Z., Liu, C., Zhao, D., Wang, Y., Du, Y.-P., Zhu, Y.-C., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03140-y · Cited by 20
A N7-methylguanosine modified circular RNA, circIPP2A2, promotes malignant behaviors in hepatocellular carcinoma by serving as a scaffold in modulating the Hornerin/PI3K/AKT/GSK3β axis
Guo, Z., Li, Z., Guo, J., Gan, L., Mo, H., Zhang, J., Fu, Y., Wang, Y., Jin, M., Wu, Y., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07248-7 · Cited by 19
Role of peritumoral tissue analysis in predicting characteristics of hepatocellular carcinoma using ultrasound-based radiomics
Qian, H., Huang, Y., Xu, L., Fu, H., & Lu, B. (2024) · Scientific Reports · doi:10.1038/s41598-024-62457-6 · Cited by 18
Advancing Hepatocellular Carcinoma Management Through Peritumoral Radiomics: Enhancing Diagnosis, Treatment, and Prognosis
Huang, Y., & Qian, H. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s493227 · Cited by 18
Bevacizumab induces ferroptosis and enhances CD8+ T cell immune activity in liver cancer via modulating HAT1 and increasing IL-9
Hou, C., Lv, P., Yuan, H.-F., Zhao, L., Wang, Y., Zhang, H., Yang, G., & Zhang, X.-D. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01299-4 · Cited by 17
A multimodal fusion system predicting survival benefits of immune checkpoint inhibitors in unresectable hepatocellular carcinoma
Xu, J., Wang, T., Li, J., Wang, Y., Zhu, Z., Xiao, F., Wang, J., Zhang, Z., Cai, W., Song, R., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00979-6 · Cited by 17
Identification and validation of immune-related gene signature models for predicting prognosis and immunotherapy response in hepatocellular carcinoma
Liu, Z., Yang, L., Liu, C., Wang, Z., Xu, W., Lu, J., Wang, C., & Xu, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1371829 · Cited by 17
Radiomic features of primary retroperitoneal sarcomas: a prognostic study
Pasquali, S., Iadecola, S., Vanzulli, A., Infante, G., Bologna, M., Corino, V., Greco, G. F., Vigorito, R., Morosi, C., Beretta, A., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115120 · Cited by 18
Transforming acidic coiled-coil-containing protein 3-mediated lipid metabolism reprogramming impairs CD8+ T-cell cytotoxicity in hepatocellular carcinoma
Li, Y., Chen, Z., Wang, D., Du, W. T., Zhu, N., Shen, X., Mao, X., Su, Y., Qin, L., Chen, D., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02367-9 · Cited by 18
Role of UFMylation in tumorigenesis and cancer immunotherapy
Ding, L., Jiang, X. M., Li, T., & Wang, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1454823 · Cited by 18
Triterpenes from Ganoderma lucidum inhibit hepatocellular carcinoma by regulating enhancer-associated lncRNA in vivo
Zhao, R., Zhang, C., Tang, C., Wu, X., Hu, S., Luo, Q., Jia, N., Fan, L., Wang, Y., Jiang, W., et al. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118706 · Cited by 17
The Gut Microbiome Controls Liver Tumors via the Vagus NervePreprint
Bauer, K. C., Trehan, R., Ruf, B., Myojin, Y., Benmebarek, M.-R., Ma, C., Seifert, M., Nur, A., Qi, J., Huang, P., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.23.576951 · Cited by 18
Self-citation
Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204)
Jin, Z.-C., Wei, J., Xiao, Y., Si, A., Chen, J.-J., Zhu, X., Li, J., Nie, F., Ding, R., Zhou, H., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001593 · Cited by 16
Self-citation
Intercellular crosstalk between cancer cells and cancer-associated fibroblasts via exosomes in gastrointestinal tumors
Cao, L., & Ouyang, H. W. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1374742 · Cited by 15
Dihydroartemisinin breaks the positive feedback loop of YAP1 and GLUT1-mediated aerobic glycolysis to boost the CD8+ effector T cells in hepatocellular carcinoma
Gao, Y., Gong, Y., Lu, J., Yang, Y., Zhang, Y., Xiong, Y., & Shi, X. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116294 · Cited by 15
A novel hybrid model for predicting tertiary lymphoid structures and targeted immunotherapy outcomes in hepatocellular carcinoma: a multicenter retrospective study
Li, Y., Li, X., Xiao, X., Cheng, J., Liu, C., Liu, C., Cai, P., Chen, W., Zhang, H., & Li, X. (2024) · European Radiology · doi:10.1007/s00330-024-11255-9 · Cited by 15
Programmed Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor and Monitor of Response to Atezolizumab plus Bevacizumab Treatment in Patients with Hepatocellular Carcinoma
Nosaka, T., Murata, Y., Akazawa, Y., Tanaka, T., Takahashi, K., Naito, T., Matsuda, H., Ohtani, M., Imamura, Y., & Nakamoto, Y. (2024) · Cancers · doi:10.3390/cancers16091785 · Cited by 14
Complete Response to Immunotherapy in Patients With Hepatocellular Carcinoma
Lim, M., Espinoza, M., Huang, Y., Franses, J. W., Zhu, H., & Hsiehchen, D. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.61735 · Cited by 14
Sophisticated roles of tumor microenvironment in resistance to immune checkpoint blockade therapy in hepatocellular carcinoma
Zhang, Y., Ma, Y., Ma, E., Chen, X., Zhang, Y., Yin, B., & Zhao, J. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2024.165 · Cited by 14
A disulfidptosis-related lncRNA signature for analyzing tumor microenvironment and clinical prognosis in hepatocellular carcinoma
Zheng, H., Cheng, J., Zhuang, Z., Li, D., Yang, J., Yuan, F., Fan, X., & Liu, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1412277 · Cited by 13
Spatial Organization of Macrophages in CTL-Rich Hepatocellular Carcinoma Influences CTL Antitumor Activity
Weng, Y., Wang, L., Wang, Y., Xu, J., Fan, X., Luo, S., Hua, Q., Xu, J., Liu, G., Zhao, K.-B., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0589 · Cited by 13
Endothelial OX40 activation facilitates tumor cell escape from T cell surveillance through S1P/YAP-mediated angiogenesis
He, B., Zhao, R., Zhang, B., Pan, H., Liu, J., Huang, L., Wei, Y., Yang, D., Liang, J., Wang, M., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186291 · Cited by 12
Combination immunotherapy targeting LAG-3, PD-1 and STING suppresses hepatocellular carcinoma as monitored by LAG-3 targeted PET imaging
Quan, Z., Gao, Y., Sun, B., Guo, Y., Jin, Z., Hao, N., Jiang, D., Zheng, C., Li, X., & Chen, Q. (2025) · Biomarker Research · doi:10.1186/s40364-025-00820-z · Cited by 12
Gut microbiome, a novel precision medicine biomarker for hepatocellular carcinoma
Chen, P., Devkota, S., Shiao, S. L., Hendifar, A. E., & Yang, J. D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1568962 · Cited by 12
Noncoding RNAs in Hepatocellular Carcinoma: Potential Applications in Combined Therapeutic Strategies and Promising Candidates of Treatment Response
Vianello, C., Monti, E., Leoni, I., Galvani, G., Giovannini, C., Piscaglia, F., Stefanelli, C., Gramantieri, L., & Fornari, F. (2024) · Cancers · doi:10.3390/cancers16040766 · Cited by 11
Intertumoral Heterogeneity Based on MRI Radiomic Features Estimates Recurrence in Hepatocellular Carcinoma
Dong, M., Li, C., Zhang, L., Zhou, J., Xiao, Y., Zhang, T., Jin, X., Fang, Z., Zhang, L., Han, Y., et al. (2024) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.29428 · Cited by 11
Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma
Urquijo-Ponce, J. J., Mateu, C. A., Sánchez, M. L., Castelló-Miralles, I., & Diago, M. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i19.2512 · Cited by 13
Unveiling Tim-3 immune checkpoint expression in hepatocellular carcinoma through abdominal contrast-enhanced CT habitat radiomics
Tang, Z., Wang, W., Gao, B., Liu, X., Liu, X., Zhuo, Y., Du, J., Ai, F., Yang, X., & Gu, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1456748 · Cited by 11
Global research trends on biomarkers for cancer immunotherapy: Visualization and bibliometric analysis
Qiao, Y., Xie, D., Li, Z., Cao, S., & Zhao, D. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2435598 · Cited by 12
Comprehensive insights into systemic therapy for the whole-course management of hepatocellular carcinoma
Jiang, J., Feng, K., Zhang, L., & Ma, K. (2025) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000086 · Cited by 10
Machine learning-based radiomics model: prognostic prediction and mechanism exploration in patients with endometrial cancer
Zhang, Y., Bao, X., Wang, Y., Li, L., Liu, L., & Wu, Q. (2025) · Biomarker Research · doi:10.1186/s40364-025-00836-5 · Cited by 10
Peripheral blood PD-1+ T lymphocytes as biomarkers in liquid biopsies for solid tumors: Clinical significance and prognostic applications
Piao, M., Zhang, N., Li, J., Li, C., Xun, Z., Zhang, L., Wang, S., Sun, B., Li, S., Xu, Y., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114052 · Cited by 9
Integrated single-cell transcriptome and TCR profiles of hepatocellular carcinoma highlight the convergence on interferon signaling during immunotherapy
Li, T., Guo, S., Xu, C., Zhang, M., Lyu, C., Xu, H., Hou, Z., Zhang, M., Li, X., Ren, J., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010534 · Cited by 9
Advancements in immunotherapy for hepatocellular carcinoma
Ascari, S., Chen, R., Vivaldi, C., Stefanini, B., Sinno, A. D., Dalbeni, A., Federico, P., & Tovoli, F. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2461631 · Cited by 8
A novel liver-function-indicators-based prognosis signature for patients with hepatocellular carcinoma treated with anti-programmed cell death-1 therapy
Zheng, Z., Mei, J., Guan, R., Zhang, J., Xiong, X., Gan, J., Li, S., & Guo, R. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03713-6 · Cited by 8
Reliable Performance of mALBI Grade‐Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First‐Line Treatment: Comparative Analysis of 13 Risk Models
Hatanaka, T., Kakizaki, S., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16871 · Cited by 8
Spatial multi-omics and deep learning reveal fingerprints of immunotherapy response and resistance in hepatocellular carcinomaPreprint
Wu, Z., Boen, J., Jindal, S., Basu, S., Bieniosek, M. F., He, S., LaPelusa, M. B., Mayer, A. T., Kaseb, A. O., Zou, J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.11.656869 · Cited by 11
Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment
Zhao, H., Ren, R., Zhang, X., Zhan, M., Cui, J., Zhang, J., Liu, X., Wu, L., Chen, Y., Zhou, Y. J., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-1298 · Cited by 7
Natural exosome-like nanovesicles from Salvia chinensis Benth induce ferroptosis to suppress hepatocellular carcinoma progression via AMPK/Nrf2/xCT axis
Liang, Z., Fang, X., Zhang, Z., Tao, M., Gong, W.-H., Jian, H., Tan, X., & Zeng, P. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111928 · Cited by 8
Biomaterials for biomarker imaging and detection
Wang, Y., Huang, X., Wu, G., Wu, W., Li, S., Su, C., Li, L., & Lv, Q. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.07.049 · Cited by 10
Acteoside as a rising star for clinical treatment: Current fundamental research and future outlooks
Zhang, F.-K., Jia, K., Wang, H., Liu, R., Xue, X., Huo, Z.-X., & Li, X. (2025) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2025.08.007 · Cited by 7
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Scheiner, B., Lombardi, P., D’Alessio, A., Kim, G., Tafavvoghi, M., Petrenko, O., Goldin, R. D., Fulgenzi, C. A. M., Torkpour, A., Balcar, L., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010975 · Cited by 7
Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab
Kocheise, L., Kempski, J., Tang, Y., Balcar, L., Berger, V., Tomczak, M., Gorgulho, J., Masood, R., Giehren, F., Schmidt, C., et al. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.102138 · Cited by 7
From Theory to Practice: Which Biomarkers Are Ready for Predicting Response in Advanced HCC ?
Decraecker, M., Blanc, J., Amintas, S., & Manaud, G. (2026) · Liver International · doi:10.1111/liv.70684 · Cited by 7
Radio-immunomics in hepatocellular carcinoma: Unraveling the tumor immune microenvironment
Liu, Q., Zhu, W., Song, F., Lou, T., He, L., Zhou, W., & Feng, Z. (2024) · Meta-Radiology · doi:10.1016/j.metrad.2024.100098 · Cited by 7
Serial Changes of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab
Murata, Y., Nosaka, T., Akazawa, Y., Tanaka, T., Takahashi, K., Naito, T., Matsuda, H., Ohtani, M., & Nakamoto, Y. (2024) · Cancers · doi:10.3390/cancers16132410 · Cited by 7
Golgi protein 73: the driver of inflammation in the immune and tumor microenvironment
Feng, P., Hu, X., Zhou, S., Liu, X., Zeng, L., & Liu, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1508034 · Cited by 7
Epidemiological characteristics and precise prophylaxis and control of HBV-associated primary liver cancer
Feng, Y., Fang, L., & Cao, G. (2025) · Hepatoma Research · doi:10.20517/2394-5079.2024.132 · Cited by 9
Multiplex immunohistochemistry to explore the tumor immune microenvironment in HCC patients with different GPC3 expression
Zhou, M., Zhou, Z., Hu, L., Chen, S., Meng, F., Chen, J., & Shen, J. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06106-0 · Cited by 7
An integrated platform for decoding hydrophilic peptide fingerprints of hepatocellular carcinoma using artificial intelligence and two-dimensional nanosheets
Li, Z., Ma, B., Shui, S., Tu, Z., Peng, W., Chen, Y., Zhou, J., Lan, F., Ying, B., & Wu, Y. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb00700j · Cited by 6
Integrating anoikis and ErbB signaling insights with machine learning and single-cell analysis for predicting prognosis and immune-targeted therapy outcomes in hepatocellular carcinoma
Fang, H., Chen, X., Zhong, Y., Wu, S., Ke, Q., Huang, Q., Wang, L., & Zhang, K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1446961 · Cited by 7
Hollow MnO2@PDLIM2 nanoplatform inhibits hepatocellular carcinoma immune evasion and progression by regulating TBK1
Liu, Z., Hu, Q., Wang, J., Zhu, X., Sun, J., Zhang, G., Fang, R., Wang, R., Zhang, B., Shi, H., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.161835 · Cited by 6
Predicting Immunotherapy Response in Unresectable Hepatocellular Carcinoma: A Comparative Study of Large Language Models and Human Experts
Xu, J., Wang, J., Li, J., Zhu, Z., Xiao, F., Cai, W., Song, R., Wang, T. F., & Li, H. (2025) · Journal of Medical Systems · doi:10.1007/s10916-025-02192-1 · Cited by 9
A Novel Nomogram to Predict Prognosis in Elderly Early-Stage Hepatocellular Carcinoma Patients After Ablation Therapy
Tang, X., Wang, Q., Jin, R., & Hu, C. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s459250 · Cited by 6
Prognostic Significance of Glypican-3 Expression in Hepatocellular Carcinoma Treated with Atezolizumab-Bevacizumab
Kim, J. H., Han, J. W., Cho, H. S., Jang, J. W., Tak, K. Y., & Sung, P. S. (2025) · Cancers · doi:10.3390/cancers17243967 · Cited by 7
NRF2–COX2–PGE2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinoma
Yamamoto, S., Kodama, T., Kuwano, A., Maesaka, K., Hashidate‐Yoshida, T., Shindou, H., Takeda, H., Shirai, K., Myojin, Y., Murai, K., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001677 · Cited by 6
AARS1 promotes tumor progression and immune evasion via ATF6 lactylation-mediated tryptophan metabolism in hepatocellular carcinoma
Wang, Y., Li, F., Li, J., Huang, T., Huang, T., Zhang, N., Li, Y., Xun, Z., Zhu, Z., Tan, Q., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.06.003 · Cited by 5
The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Lymphocyte-to-Monocyte Ratio in Patients with Hepatocellular Carcinoma Receiving HAIC-Based Conversion Hepatectomy: A Dual-Center Retrospective Cohort Study
Li, D., Fan, Y., He, B., Tang, Y., Deng, G., Guo, R., Deng, M., & Tang, D. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s523194 · Cited by 5
Identification of Two Distinct Immune Subtypes in Hepatitis B Virus (HBV)-Associated Hepatocellular Carcinoma (HCC)
Battista, D. D., Yakymi, R., Scheibe, E., Sato, S., Gerstein, H., Markowitz, T. E., Lack, J., Mereu, R., Manieli, C., Zamboni, F., et al. (2024) · Cancers · doi:10.3390/cancers16071370 · Cited by 5
Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
Nishida, N. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0739 · Cited by 5
Single-Cell Transcriptomic Profiling Reveals That Macrophage-Induced Angiogenesis Contributes to Immunotherapy Resistance in Hepatocellular Carcinoma
Pan, X., Liao, B., Hu, Z., & Xiong, Y. (2026) · Biology · doi:10.3390/biology15010095 · Cited by 4
Prognostic model development using novel genetic signature associated with adenosine metabolism and immune status for patients with hepatocellular carcinoma
Chen, Y., Wang, K., Zhang, X., Tao, D., Shang, Y., Wang, P., Li, Q., & Liu, Y. (2024) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-024-01061-8 · Cited by 4

Authors: Greten, T. F., Villanueva, A., Korangy, F., Ruf, B., Yarchoan, M., Ma, L., Ruppin, E., & Wang, X. W.
Affiliations: National Institutes of Health (US)
Tisch Cancer Institute (US)
National Cancer Institute (US)
Johns Hopkins University (US)
Corresponding author: Greten, Tim F.
ORCID: Greten, Tim F.
Villanueva, Augusto
Korangy, Firouzeh
Ruf, Benjamin
Yarchoan, Mark
Ma, Lichun
Ruppin, Eytan
Wang, Xin W.
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2023-09-19
Volume: 20
Issue: 11
Pages: 780-798
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/s41571-023-00816-4
OpenAlex: W4386845699
Cited by: 227
References: 205
Citations by year: 2026: 66 · 2025: 88 · 2024: 71 · 2023: 2
FWCI: 7.38
Type: journal article
Language: en
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords: hepatocellular carcinoma, immune checkpoint inhibitors, predictive biomarkers, atezolizumab plus bevacizumab, single-cell RNA sequencing, circulating tumor cells, high-dimensional flow cytometry, tumor microbiome, radiomics, gene expression signatures, spatial transcriptomics, biomarker-driven trials, immunotherapy selection
MeSH terms: Sorafenib, Carcinoma, Hepatocellular, Humans, Immunotherapy, Liver Neoplasms, Biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Biomarkers for immunotherapy of hepatocellular carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks